Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost-effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.735
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Cost effectiveness of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years with diabetes in the United States. Poster presented at the American Diabetes Association's 84th Scientific Sessions; June 21, 2024. Orlando, FL. [abstract] Diabetes. 2024 Jun; 73(Suppl 1):1045.
Buck P, Graham J, Grace M, Myers E, Diaz-Decaro J. The public health impact of vaccination strategies in 16-to-40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United States. Poster presented at the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 24, 2024. Copenhagen, Germany.
La E, Singer D, Graham J, Grace M, Molnar D. Modeled public health impact of increasing respiratory syncytial virus vaccination coverage among adults Aged ≥ 60 years in the United States. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024.
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled burden of RSV in adults aged 50-59 years with chronic cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.
Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled impact of adjuvanted RSVPREF3 vaccination on RSV-related health outcomes in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.